A-CURE

INTERVENTIONAL CARDIOLOGY REVIEW
Dr Burkhoff introduced the meeting by emphasising the need for consistent terminology in the field of acute cardiac unloading. The proposed definition of unloading is the reduction of total mechanical power expenditure of the ventricle, which correlates with reductions in myocardial oxygen consumption and haemodynamic forces that lead to ventricular remodelling.
The aim of myocardial unloading is twofold: first to achieve myocardial salvage and second to prevent heart failure (HF) and cardiac remodelling. It is important to recognise these as two distinct and important goals of acute cardiac unloading.
The benefits of left venticle (LV) unloading are well documented in both basic and clinical literature. Pharmacological unloading using captopril, an angiotensin-converting enzyme inhibitor, in an animal model of myocardial infarctino (MI) was first reported in 1985, and showed a shift in the end diastolic pressure. 1 Following this initial study, the shift from basic to clinical research occurred rapidly.
Clinical trials showed that, after anterior MI, ventricular dilation is progressive and that captropril may curtail the process, as well as reducing filling pressures and improving exercise tolerance. 2 However, there are inherent limitations to pharmacological approaches to myocardial unloading. Unloading the LV and decreasing heart rate by these methods leads to a corresponding compromise in aortic pressure and cardiac output. Appropriate device-based therapies can overcome these limitations, as well as facilitating optimal use of other pharmacological or device-based therapies. These can have synergistic effects.
A 2003 study by Meyns et al. showed that by providing LV support using a catheter-mounted axial flow pump during the ischaemic period and during reperfusion the infarct size was reduced in animal models. Furthermore, oxygen demand during unloading is not an 'allor-nothing' phenomenon, but there is a dose-dependence; the more unloading is achieved, the more oxygen demand can be reduced during the ischaemic period and during reperfusion, and the more myocardial salvage can be achieved. 3 Since the publication of this study, a growing body of literature has established the benefits of mechanical myocardial unloading, [4] [5] [6] [7] [8] and has led to the increased clinical application of the technique.
The difference between myocardial unloading using drugs and devices can be demonstrated by examining the impact of LV-aorta (LV-Ao) assist devices on haemodynamics and energetics. An LV-Ao device takes blood directly from the LV to the aorta and maintains systemic and coronary perfusion pressures while simultaneously unloading the ventricle -a phenomenon known as LV-aortic pressure uncoupling.
Uncoupling the LV from the systemic circulation minimises the mechanical work of the heart. This concept is the essence of the differences between drugs and devices and explains why devices are more effective than drugs alone in unloading the LV.
Dr Burkhoff emphasised that the determinants of myocardial oxygen consumption are not solely determined by the stroke work of the heart. This is important to remember when comparing different modes of mechanical circulatory support such as the left ventricular assist device (LVAD), which takes blood from the LV to the aorta and ECMO, which takes blood from the right atrium to the aorta. The oxygen consumption of the heart is linearly related to a parameter known as the pressure volume area (PVA) (see Figure 1) . This is the sum of the stroke work and the potential energy, i.e. the energy that is stored in the myocardial filaments after contraction rather than being released as external work. It is also important to note that even when the heart is producing no external work, it still consumes energy, largely due to calcium cycling, but also due to basal metabolism. As drugs increase contractility, they increase oxygen consumption independent of the 
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Dr Burkhoff is an Associate Professor of Medicine at Columbia University, Division of Cardiology. He has authored more than 300 peerreviewed publications and is a world expert in heart failure, haemodynamics, and heart muscle mechanics. Dr Burkhoff is a founding member of the A-CURE Working Group and Co-Chair of the 2017 A-CURE Symposium. It is also important to understand that the effects of unloading are not restricted to the acute phase, and ventricular support has known consequences on ventricular remodelling associated with HF. Longterm mechanical unloading of the failing ventricle can, under certain conditions, lead to reverse remodelling, a restoration of a normal pressure-volume relationship in failing heart. Sustained unloading offers the potential for significant and sustained myocardial recovery through this reverse remodelling process; this was first reported in human hearts in 1996. 9 Studies of LV unloading are still in their infancy but basic research is accelerating, and clinical studies are in their early stages. Therefore, Dr Burkhoff stressed the need to introduce consistency in the literature and into clinical studies, not only in terminology, but also in methodologies. We need to think critically of the methodologies that are being used, particularly in terms of measuring pressure-volume loops. It is difficult to compare studies that enrol different patient populations. It is also important to be consistent in the definition of clinical trial endpoints.
With respect to terminology, it is essential to understand the difference between support and unloading, and their dose-dependence (see Figure 2) . Partial support and partial unloading occurs when the heart continues to provide some of the cardiac output while the device provides the remainder. This results in decreased myocardial oxygen demand and a small reduction in the PVA. In full support/partial unloading, the entire cardiac output is provided by the device, and there is still a volume cycle in the ventricle to generate some LV pressures throughout the cardiac cycle. In this scenario, the aortic pressure is uncoupled from ventricular function, and the pressure-volume loop shifts further leftwards and myocardial oxygen consumption is further decreased. Only when the ventricle is fully unloaded and the heart is performing zero work, i.e. during full support/full unloading, is myocardial oxygen consumption minimised. This shifts the pressurevolume relationship further leftward, almost obliterating the PVA.
This emphasises the fact that unloading is dose-dependent and, in clinical practice, the flow rate of a device may have a different impact on different patients depending on their loading conditions that result from the use of the device.
In his closing remarks, Dr Burkhoff also highlighted the Training and Education in Advanced Cardiovascular Haemodynamics (TEACH) training initiative that aims to enhance the understanding of basic haemodynamic principles. This will involve two courses that will be held at Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting 2017 (www.tctmd.com, www.crfteach.com and www.pvloops.com). Myocardial infarct size remains an important target of therapy. 1 However, even if infarct size is reduced following an MI, if the haemodynamics are consistent with HF, this will remain a major cause of mortality for patients. 2 Two years ago, Dr Kapur's team published the concept of the primary unloading hypothesis, which suggested that first unloading the LV, then delaying reperfusion, activates a cardioprotective programme that limits myocardial damage in acute MI ( Figure 1) . 3 This study also identified an early molecular signal, release of the cytokine stromal-derived factor 1 alpha (SDF-1-alpha), which is known to be cardioprotective. This correlated with infarct size and led to the hypothesis that mechanical unloading leads to an increase in the SDF-1 CXCR4 signalling pathway, which is linked to a number of other cardioprotective mediators, including protein kinase B, extracellular signal-regulated kinase and glycogen synthase kinase 3 beta. This results in a shift to a cardioprotective phenotype.
Another important question concerns the kinetics of primary unloading: how important is the delay to reperfusion? Dr Kapur's team tested the idea of delaying reperfusion after activating the Impella device by 15, 30 or 60 minutes. Delaying reperfusion appeared to be necessary for reducing infarct size (see Figure 2) . 4 One possible reason for this is that functional reperfusion may reduce the area of risk. With the left anterior descending artery (LAD) still occluded, enhanced collateral flow through non-occluded vessels may lead to a reduction in the area at risk. This may, in part, drive the benefits in terms of reducing infarct size.
The release of SDF-1-alpha in ventricular tissue is highest after a 30-minute delay in reperfusion. In order to fully understand the biological A-CURE mechanisms underlying unloading, it was important to explore the cause of this release. SDF-1-alpha is ubiquitously expressed, but is rapidly degraded by a number of metalloproteases as well as dipeptidyl peptidase-4 (DPP4) and the CXCR7 pathway. 5 Further study revealed that primary unloading reduces the activity of these proteases that promote SDF-1-alpha degradation. Dr Kapur's team is currently investigating the hypothesis that, by reducing the activity of these degradation pathways, primary unloading can increase the concentration of SDF-1-alpha in the myocardium, particularly during acute injury, leading to a protective phenotype that increases cell survival ( Figure 3) . 6 It is known that ischaemic injury leads to an uncoupling of SDF-1-alpha and CXCR signalling. 7 Dr Kapur suggested that primary unloading re-aligns the SDF-1-alpha:CXCR signalling axis, which is vital for myocardial repair.
An important question to address was whether the acute cardioprotective effect of primary unloading provides a durable reduction in HF. The cardiac response to increased work includes a reactivation of foetal genes, and remodelling following acute MI is largely driven by the foetal gene programme. 8 An animal study found that, compared to primary reperfusion, primary unloading reduces LV scar and preserves cardiac output at 30 days after acute MI. 6 No early signs of change in cardiac volume were seen but this may be due to the short timescale of the study. The study also showed that, at 30 days, primary unloading limits the activation of a gene programme associated with maladaptive cardiac remodelling. It also reduces tissue expression and circulating levels of brain natriuretic peptide, an important marker of HF, and increases the circulating levels of SDF-1-alpha in the first week, which correlates directly with reduction of scar size. Primary unloading appears to mechanically reprogramme myocardial responses to injury in acute MI, which involves the foetal gene programme. Dr Kapur concluded by reminding the audience that, in 2015, it was predicted that mechanical preconditioning would not translate into a successful clinical strategy that reduces myocardial infarct size. 10 In 2017, the US Food and Drug Administration approved a Phase I clinical trial examining the safety and feasibility of primary unloading. The follow-up and larger Phase IIb study (CUPID 2) is the largest gene transfer study carried out in humans to date (n=250). However, AAV1/SERCA2a at the dose tested did not show an improvement in the primary endpoint. 4 Possible reasons for this disappointing result include insufficient myocardial uptake, because the AAV concentration was too low (the US Food and Drug Administration did not allow the use of higher doses), and the method of gene transfer was inadequate. While previous data in animals had showed a high percentage of infected cardiomyocytes (30-75 %), data from CUPID 2 showed that the uptake in humans was much lower (<0.5-1 %).
The method of gene transfer in CUPID 2 trial was clearly inadequate.
Dr Hajjar presented his current hypothesis that involves improving gene delivery by using the Impella device to enhance viral uptake. He proposed that Impella support could affect uptake in two ways. First, viral uptake is adversely affected by increased left ventricle (LV) diameter, end diastolic pressure and sympathetic activation, leading to increased wall stress.
Further, the inflammation, cell death, ischaemia and myocyte destruction at the time of a myocardial infarction (MI) also provides a hostile environment for vectors. Acute unloading with the Impella mitigates these adverse conditions. Second, the Impella could be used to haemodynamically support the patient while the vector is delivered into the coronary system during temporary coronary balloon occlusion. This would allow for a longer dwell time and minimise the risk of haemodynamic collapse.
Dr Hajjar presented data from his current studies. In a porcine model of subacute ischaemic HF, MI is induced, and the heart is allowed to remodel for 2 weeks. Gene delivery under Impella support then commences at this time point. Early data shows that this approach reduces LV wall stress, decreases end diastolic pressure, increases epicardial coronary flow, and increases myocardial perfusion, specifically in the infarct region (see Figure 1) . 5 Thus far, all pigs receiving Impella support during vector delivery while occluding the coronary artery have been successfully bridged through the procedure without incident, while all pigs that did not receive mechanical support suffered haemodynamic collapse and required cardioversion or other intervention. Following the induction of profound CS, six pigs were treated with VA-ECMO, and six pigs treated with the Impella CP. 2 As expected, the afterload was increased with ECMO, and the pressure-volume loop initially shifted rightward (reflecting increased myocardial work), but eventually resulted in a small leftward shift, likely reflecting the recovery of contractility while on support. In contrast, the Impella was found to provide almost full support immediately, giving partial unloading with low pulsatility, then the LV recovered. The PVA and LVEDP were significantly higher in CS pigs treated with the ECMO compared with Impella. Lactate was normalised in both groups.
However, the ECMO-treated animals immediately restored renal perfusion, and this aspect was more efficient than the Impella. In conclusion, these ongoing studies hope to demonstrate that by enhancing coronary flow, perfusion pressure can be increased while at the same time the unloading will allow a better environment for more aggressive gene delivery. In 2016, the mean survival rate was 58 %, a relative improvement of 14 % since the US Food and Drug Administration (FDA) approval on the Impella. 3 One factor observed to be associated with early mortality in AMI/CS is increased inotrope exposure. 4 This does not determine causality as the severity of a patient's condition correlates with the number of inotropes and vasopressors. Nevertheless, it is likely that the load of inotropes and vasopressors directly influences outcomes. 5 Similarly, a delay in support is clearly associated with mortality in AMI/CS. Data indicate that if a patient receives mechanical circulatory support (MCS) in the first 75 minutes following AMI, outcomes are substantially improved compared with those who have a longer delay in support (see Figure 1) . 5 In addition, the use of haemodynamic support prior to percutaneous coronary intervention (PCI) has been shown to improve survival, due to effects on the reperfusion injury and ischaemia (see Dr Navin Kapur's talk). The separation of the Kaplan-Meier curves occurs very early following PCI, reinforcing the idea that early MCS is a key determinant in clinical outcomes (see 
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In conclusion, this study confirms the ability of the Impella CP to unload the heart efficiently and effectively while providing increased tissue perfusion. However, ECMO is superior in restoring systemic perfusion in the acute stages of support. Chronic studies would be necessary to assess the effect of both platforms on restoring systemic perfusion relevant to the clinical setting. Figure 3) . 6 This protocol is specific to a defined group of patients, and has proscribed exclusion and inclusion criteria. Although this was a protocol-led treatment, individual decisions were based on operator preference. Nevertheless, this approach allows for better assessment of real-world outcomes. The protocol was Using this protocol, the Detroit CSI pilot study has been initiated and has treated 41 patients at the time of the A-CURE Symposium. The average age of participants was 65 years, and 70 % were male. A total of 95 % were taking vasopressors and 41 % were in cardiac arrest. 6 This patient populations is similar to that of the SHOCK trial (n=302). 7 The population differed from that in the Impella versus Intra-Aortic Balloon Pump in Cardiogenic Shock (IMPRESS) trial (n=48), a prospective trial in which the patients were much sicker, all were mechanically ventilated and 92 % had a cardiac arrest. 8 In the Detroit CSI study, the median lactate levels were 4.7 g/dl compared with 8.2 g/dl in the IMPRESS trial.
Of 55 screened patients, 14 were excluded based on the inclusion/ exclusion criteria. The pilot study showed favourable outcomes. Outof-hospital cardiac arrest occurred in 6 participants and there were 11 in-hospital cardiac arrests. Overall survival rate was 76 %, compared A subsequent study assessed the acute effects of LVAD support on systemic haemodynamics, LV mechano-energetics, and myocardial oxygen consumption (MVO 2 ) in vivo. 2 The study involved 12 mixedbreed sheep (34 to 54 kg), which were given acute LVAD support. with 53 % in the SHOCK trial and 53 % in IMPRESS. 7, 8 Implantation of Impella prior to PCI occurred in 66 % of participants and there was a 66 % improvement in cardiac power output (0.57 W to 0.95 %; P<0.001) after the initiation of MCS and PCI. Of note, as the study progressed, protocol adherence increased, with a corresponding improvement in outcomes. 6 In conclusion, rapid early delivery of MCS guided by invasive haemodynamic monitoring is associated with significantly improved survival in an AMI/CS patient population. This multi-institutional effort demonstrates the effectiveness of an institutionalised protocol to address CS and significantly improve patient outcomes in this difficult patient cohort. Dr Basir described this as a "war on shock", which involves a systematic team effort using regional shock protocols that can be summarised as follows: is observed when the therapy is applied within 2 hours of the patient presenting at the hospital. 1 This has led to the adoption of a target 90 minutes DTB time. However, the maximal effect of DTB time may have been reached. Recent data have indicated that while the average DTB has fallen well below 90 minutes, a corresponding drop in mortality rates of MI patients has not been observed. 2 Additional strategies are therefore needed to reduce in-hospital mortality rates in this population.
Understanding the balance between myocardial oxygen supply and demand in MI has enabled us to develop effective left ventricle (LV) unloading protocols. 3, 4 Numerous preclinical investigations have supported the hypothesis that primary LV unloading and delaying coronary reperfusion provides both cardioprotective signalling and myocardial salvage. These scientific investigations have in part led to a recent paradigm shift in acute MI management that proposes door-tosupport time as an emerging target of therapy to reduce reperfusion injury and improve outcomes associated with MI/CS. 5 In late 2016 the US Food and Drug Administration gave approval for the Door to Unloading (DTU) in ST-segment elevation MI (STEMI) safety and feasibility study. This study is a prospective feasibility study to evaluate the use of the Impella CP device for unloading of the LV prior to primary percutaneous coronary intervention (PPCI) in patients presenting with acute STEMI, without CS. 6 The main inclusion criteria are age 21-80 years, first MI and acute anterior STEMI with ≥2 mm in two or more contiguous anterior leads or ≥4 mm total ST-segment deviation sum in the anterior leads, and presentation between 1 and 6 hours of symptom onset.
Patients are randomised to two treatment arms: immediate Impella implantation followed by 30 minutes of mechanical unloading prior to PPCI, or immediate Impella implantation directly followed by PPCI. The Impella is explanted after 3-4 hours of support. This time was chosen as the optimal unloading time is not known and the implications for leaving in a 14 Fr sheath for longer than 4 hours may have safety implications. The primary endpoints are the composite of cardiovascular mortality, re-infarction, stroke or transient ischaemic attack, major vascular complication at 30 days, and also an additional exploratory efficacy endpoint of the infarct size as percentage of LV mass, evaluated by cardiac magnetic resonance (CMR) at 30 days post-PPCI (see Figure 1 ).
The first patient was enrolled in April 2017. To date, all patients have met the <90 min DTB times, including those who had delayed reperfusion. The DTU metric will be determined for each patient as the study continues. We will need an understanding of 3-to 5-day and 30-day magnetic resonance imaging (MRI) to guide optimisation of infarct size reduction. Results from these patients will be used to guide best practices for the pivotal study. Given the design of the study and In summary, this ongoing study has a strong focus on safety, using large bore access and device therapy. Appropriate patient selection is key to help us to understand the physiology and clinical correlates to DTU and how to use concomitant therapies to improve patient outcomes. 
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Dr Tschöpe is a Professor of Medicine and Cardiology and the Vice Director of the Department of Cardiology, Charité, CVK, Berlin, guiding the cardiomyopathy programme. His main research interests are the potential of cell therapies to cure heart failure and the role of the immune system in heart failure. Acute fulminant myocarditis and giant cell myocarditis have a poor prognosis. 1 At present, short-term mechanical circulatory support (MCS) for myocarditis patients with refractory cardiogenic shock (CS) has predominantly used extracorporeal membrane oxygenation
MACCE = major adverse cardiac and cerebrovascular event; aMI = myocardial infarction; d = days; PPCI = primary percutaneous coronary intervention; STEMI = ST-elevation myocardial infarction; TIA = transient ischaemic attack.
(ECMO), 2 despite the use of Impella CP ® for all other CS situations. Several case reports of successful short-term use of the Impella in fulminant myocarditis and giant cell myocarditis have been published. [3] [4] [5] [6] [7] These reports have suggested that peripheral unloading with the Impella may not be merely providing circulatory support, but it also may be conferring additional anti-inflammatory effects that modify the disease state, thus allowing a bridge to recovery in patients with fulminant myocarditis. In order to explore this hypothesis further, Dr Tschöpe presented the known pathophysiological processes underlying myocarditis, including pro-inflammatory and fibrotic processes that lead to cardiac remodelling and failure during disease progression. In an overloaded myocardium such as is present during fulminant myocarditis, mechanical stress activates integrins (mechanoreceptors) in the heart, which are known to mediate pro-inflammatory and fibrotic processes.
Furthermore, integrins are known to have direct detrimental effects on the contractile apparatus. These combined effects exacerbate myocarditis, and contribute to the observed poor patient outcomes. Therefore, the hypothesis is logically raised whether haemodynamically unloading the heart by means of MCS (thereby decreasing mechanical stress) is a sufficient means to overcoming these pathophysiological mechanisms.
The hypothesis that mechanical unloading may improve reverse remodelling in fulminant myocarditis was tested in a 62-yearold patient recently admitted to the practice of Dr Tschöpe with severe myocarditis and pre-CS despite immunosuppressive therapy.
An axillary Impella 5.0 was implanted, which remained in place for 40 days. After 2 days in bed, the patient was mobile. Steroid therapy and unloading gave a significant improvement in ejection fraction from 5 days after implantation. In addition, the patient's NT-pro brain natriuretic peptide levels reduced over time (see Figure 1) , and increases were seen in EF and global longitudinal strain during short-time loading (see Figure 2) . After 4 weeks, an echocardiogram showed the first signs of recovery.
Serial left ventricular biopsies taken at various time points during treatment to assess biomarkers of inflammation. These data demonstrate that the inflammatory response was significantly reduced during the time of Impella support. During this time steroids were also applied to decrease the inflammatory response. However, importantly, when the Impella was removed, the inflammatory response significantly increased, despite continued steroid use (see Figure 3 ). This suggests that Impella support may provide clinically important additional antiinflammatory benefits beyond that observed with steroids alone.
This pattern was seen for the levels of adhesion molecules ICAM-1 and VCAM-1, and also integrin receptors. Mass spectroscopic analysis of the biopsy samples revealed significant changes in protein composition, notably in the matrix proteins collagen and vimentin, which are important for integrin function. There was also a rapid improvement in titin function after unloading, which is essential for maintaining the elasticity of cardiomyocytes. Finally, energy consumption was assessed by measurement of glucose uptake and mitochondrial malate dehydrogenase. Again, a significant improvement was seen during the period of mechanical unloading. 8 In conclusion, experience to date supports the hypothesis that prolonged unloading with an Impella device offers circulatory support with additional disease-modifying effects that are important for bridging fulminant myocarditis patients to recovery. The Impella RP is a modified version of the Impella CP that is designed for right heart support. One important difference is that, rather than pulling blood, it pushes blood from the inferior vena cava to the pulmonary artery. The Impella RP has received approval from the US Food and Drug Administration (FDA). 4 Approval was based on the findings of the RECOVER RIGHT study, which investigated the use of Impella RP support system in patients with RV failure (n=30). 5 Each study had two cohorts: patients with RV failure after left ventricular assist device implantation and patients with RV In conclusion, RV failure is associated with increased mortality rates and is difficult to predict and sometimes to diagnose. The Impella RP device is easy to use and consistently improves patient haemodynamics while providing ventricular unloading. The Impella RP has a favourable safety profile with low adverse events across all studies. The use of Impella RP in RVF has demonstrated improved survival. The Impella RP therefore represents a viable tool to enable recovery or as a bridge to other destination therapies.
Clinical Data and Experience With a Novel Right Ventricular Support
Device, the Impella RP 
Impella Support Improves Pulmonary Congestion in Cardiogenic Shock
Presented by Ralf Westenfeld
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Dr Westenfeld is head of the intensive care medicine and heart failure section at University Hospital, Dusseldorf, Germany. His research interests include the pathomechanisms of cardiovascular calcification, interventional treatment strategies in high-risk patients, and myocarditis and transplant rejection.
Dr Westenfeld began by describing the current state of understanding of pulmonary congestion in cardiogenic shock (CS). The evolution of systemic inflammatory response and multiple organ dysfunction syndrome following cardiopulmonary resuscitation may affect postcardiac-arrest-syndrome. 1 Acute lung injury is an unrecognised problem in patients on extracorporeal life support (ECLS) who undergo implantation of a long-term mechanical circulatory support (MCS) device. 2 In addition, early progression of pulmonary oedema (within 24 hours) has been found to predict mortality in patients with extracorporeal membrane oxygenation (ECMO). 3 Increased pulmonary congestion in patients with ECMO carries the same mortality risk as After excluding patients who died during the blanking period or those who required ECLS, 60 patients remained for analysis; 30 who received IABP and 30 who received the Impella. On admission, patient characteristics were similar between groups (see Table 1 ).
They had high serum lactate during MCS support, which was higher in the Impella group (see Table 1 ). Similarly, troponin levels, inotropic score, and levels of lactate dehydrogenase were also high, but not significantly different between groups. Data suggest that the patients treated with Impella may have been associated with increased tissue perfusion, which could lead to the observed higher lactate levels, or this group may have included sicker patients, supported by the data that an upgrade to ECLS or left ventricular assist device was needed in 10 % of the IABP group versus 33 % in the Impella group (P=0.03). Pneumonia was reported in 76 % of patients receiving IABP and 56 % receiving the Impella (P=0.18). Hospitalisation in the intensive care unit was required for 15±15 days and 24±14 days in the IABP and Impella groups, respectively (P=0.03). Total hospitalisation was 30±35 days and 48±30 days, respectively (P=0.03). At 30 days, survival was 42 % and 48 %, respectively (P=0.8).
Regarding the impact of ventricular unloading by the Impella on pulmonary congestion, a significant decrease in the Halperin score at 72 hours was observed in patients treated with Impella compared with those treated with IABP (see Figure 1) . When the entire cohort was divided into patients who did or did not experience pulmonary decongestion as defined by the Halperin score, an association was seen between reduction of pulmonary congestion within the first 24 hours and improved survival in CS (see Figure 2) . However, this Impella-dependent effect did not translate directly into a significant survival benefit in the overall cohort. Dr Westenfeld commented that in the cohort he examined, decongestion was achieved in 73 % of Impella-supported patients, but only 50 % of IABP patients. In conclusion, in this single centre study, data suggest that early progression of pulmonary oedema is associated with poor outcome in CS. Left ventricular unloading by Impella may more effectively facilitate pulmonary decongestion in CS compared with IABP support.
This study was limited by its small sample size and retrospective design. There is a need for a large-scale analysis of outcomes and confounders in large registry studies. In addition, prospective analysis is needed of pulmonary congestion in CS, using early assessment by ultrasound, guiding escalation strategies, and investigating weaning and haemodynamics. Finally, mechanistic studies in large animal models will help elucidate the effects at the molecular level in terms of mitochondrial function, reactive oxygen species production and the effects of unloading on inflammation. 2 While recent work has highlighted the rapid advances that have been made in understanding dilated cardiomyopathy, a precursor to HF, 3 and assist devices have proven effective in end-stage disease, 4 Dr Fuster emphasised the need to focus on people at high risk for HF, but without structural heart disease.
He highlighted recent additions to the guidelines that have included biomarkers that may help identify an at-risk population. 5 These include screening assays based on levels of pro-brain natriuretic peptide 6 and troponin, 7 leading to high-sensitivity cardiac troponin (hs-cTn) assays. 8 Sixyear increases in the levels of hs-cTn, suggestive of progressive myocardial damage, are independently associated with HF. 9 A risk model based on these biomarkers has been used to develop a robust tool for the prediction of cardiovascular death in patients with stable coronary heart disease. 10 Other aspects of changing approaches to CVD include a greater focus on the atherosclerotic disease burden rather than on features of individual plaques, 11 and the evolving paradigm of CVD as a systemic disease that is dependent on macrophage activity. 12 Imaging studies of patients after acute coronary syndrome (ACS) have demonstrated increased splenic metabolic activity after ACS and its association with proinflammatory remodelling of circulating leukocytes. 13 Evolving non-invasive technologies are also evaluating ischaemia at the microcirculation level.
14 In the future, Dr Fuster predicts that ischaemia of each artery will be assessed by noninvasive techniques. A-CURE cotransporter 2 inhibitors and glucagon-like peptide 1 analogues. 16 In addition, new treatment modalities for HF that are employed at the early stages of the disease are emerging, 17 and cardiovascular regenerative medicine using genetic editing is advancing rapidly and offers considerable future potential. 18 Dr Fuster turned his attention to the challenges of treating HF in older patients. Chief among his concerns was patient adherence to therapy, which has led to the development of the polypill for cardiovascular prevention. [19] [20] [21] Also important is the issue of cognitive degeneration due to microvascular disease. The cumulative burden of cardiovascular risk factors from childhood/adolescence has been associated with worse midlife cognitive performance independent of adulthood exposure. LA volume (see Figure 3) . In terms of LA function, LA ejection fraction was improved when the Impella was supporting the LV. Importantly, this was not associated with an increased atrial load, indicated by reduction of LA atrial work and developed pressure (dp/dt max) when the Impella was in place. 1 This suggested that atrial contraction was more efficient when the atrium was unloaded.
Since atrial stretch is a known mechanism for atrial arrhythmia, Dr Ishikawa's team investigated whether the use of the Impella reduced arrhythmogenesis. Using pacing of the right atrium, atrial tachycardia or atrial fibrillation was induced in the majority (70 %), while not unloaded by the Impella. By supporting these same pigs with an Impella in the LV, the rate of atrial arrhythmia was reduced to only 30 % (see Figure 4) . Furthermore, the duration of the arrhythmia events was found to correlate with the maximum LA volume, suggesting that LA stretch may play a key role in mediating the maintenance of atrial arrhythmias. 2 Dr Ishikawa's team therefore measured the expression level of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 (NOX2), a stretch-dependent source of reactive oxygen species. He found levels of NOX2 to be increased in the LA after MI compared with controls, but NOX2 levels were remained unaffected in those animals that underwent LV Impella support for 2 hours. He demonstrated that increased NOX2 levels were associated with increased phosphorylation the ryanodine receptor 2, the source of diastolic Ca 2+ leak. This increased phosphorylation was not observed in atria supported with the Impella.
In conclusion, LV unloading with the Impella CP also significantly affects the haemodynamics of the upstream LA. Directly unloading the LV with mechanical support leads to passive unloading of the LA, reduces LA stretch, and inhibits atrial arrhythmogenesis by modulating stretch-dependent oxidative stress. The plotted relationship between the pressure head and the motor current forms a hysteresis loop which is asymmetric, non-linear and changes with each cycle, making extraction of information challenging.
However, every pump exhibits the same hysteresis loop phases, making it possible to extract information about heart function such as the LV end diastolic pressure (LVEDP), peak pressure, slope of relaxation and slope of contraction.
In a recent study that aimed to validate this hypothesis, an Impella CP with both ventricular and aortic pressure sensors was implanted into a mock circulation loop. 1 The contractility was kept constant and the LVEDP was varied (see Figure 1 ). Similarly, it was possible to maintain a constant preload and vary the contractility. The motor current and aortic pressure were extracted from the console and plotted to illustrate the hysteresis relationship (see Figure 1) . These inputs were then used to calculate LVEDP and contractility measurements. Using these techniques, multiple indices of LV function may be measured.
Dr Edelman presented a flow chart describing the method for the use of device extracted metrics to predict physiological function, such as LVEDP during (see Figure 2) . 1 It is hoped that this approach to estimating metrics of heart function will be placed into next generation of Impella devices.
Swan-Ganz catheters are used in patients regularly to estimation of LVEDP with real-time wedge tracing during end-expiratory hold. This new method of estimating heart function using device derived metrics would decrease the number of catheters in patients on Impella support by having one catheter residing in the LV that provides both circulatory support and heart function information.
In summary, understanding the dynamic changes of disease progression and its effect on cardiac state allows for standardised care of the patient, as well as improved outcomes using quantitative optimisation. From the clinician point of view, it also allows determination of the optimal Impella therapy in conjunction with other forms of therapy.
Utilisation of Support Device Hysteresis to Track Cardiac Function
Presented by Elazer R Edelman however, hold more potential (see Table 1 ). A recent study found that the use of MCS during resuscitation of cardiac arrest in the catheterisation laboratory increases the rate of return of spontaneous circulation (ROSC). 2 A case series (n=8) found that use of the Impella was feasible in selected patients with cardiac arrest and gave a 6-month survival rate of 50 %. 3 The same survival rate was reported in a case series (n=14) that employed miniaturised ECMO systems. 4 Recently, Dr Lotun's team conducted a study in which 30 pigs were randomly assigned to interrupted manual chest compressions (n=10) versus either a piston chest compression device (LUCAS™; n=10) or a percutaneously inserted Impella device (n=10), supporting systemic haemodynamics and perfusion during two clinically relevant time periods of cardiac arrest associated with a left main/proximal left anterior descending (LAD) coronary occlusion in the cardiac catheterisation laboratory. 5 The primary endpoint was favourable neurological function of survivors at 24 hours. Secondary endpoints included defibrillation success, ROSC and resuscitation-generated haemodynamics.
The primary endpoint was achieved in 29 % of the LUCAS group and 33 % of the Impella group compared with none of the manual group. 5 ROSC was achieved in 78 % of the Impella group, compared with 50 % and 59 % in the manual and LUCAS groups, respectively.
In conclusion, cardiac arrest in the catheterisation laboratory is a devastating event and will be more common with increasingly complex interventional procedures. The goal of circulatory support is to provide vital organ perfusion while the operator is correcting the underlying cause. Mechanical compression devices offer unique advantages over manual compression in this setting.
The placement of percutaneous MCS devices can be considered but further studies are needed to define the optimal device and clinical outcomes. He commenced his presentation with a discussion of mitochondrial energy metabolism in the failing heart. The heart consumes more energy than any other organ. To match this high energy demand, myocardial mitochondria cycle up to 6 kg of ATP every day, which is about 20 to 30 times the heart's own weight. Myocardial mitochondrial energy metabolism in the failing heart has, therefore, become a field of considerable interest.
1,2
Increased ventricular filling pressure and volume are hallmarks of heart failure (HF) pathophysiology. 3, 4 This pressure and volume overload is linked to alterations in myocardial substrate utilisation, mitochondrial energy production, and mitochondrial reactive oxygen species formation. 5, 6 Clinical evidence suggests that ventricular unloading can reverse systemic and local metabolic dysfunction in patients with advanced HF treated with durable ventricular assist devices. 7 However, there are no functional data on mitochondrial respiration in the failing heart under these unloading conditions. Dr Scheiber's team proposed the idea that chronic left ventricular unloading in terminal patients with HF would improve myocardial mitochondrial oxidative phosphorylation and reduce myocardial mitochondrial reactive oxygen species production. In order to investigate this hypothesis, a prospective study evaluated 13 patients undergoing heart transplantation between October 2016 and July 2017.
Eight patients had a left ventricular assist device (LVAD) surgically implanted as a 'bridge to transplant' prior to heart transplantation.
Myocardial tissue specimens were harvested from macroscopically scar-free areas of the left ventricular free wall of the explanted heart. Patients did not differ significantly in age or body mass index.
The average time of unloading in the LVAD-supported patients was 20 months.
The ex vivo maximal myocardial oxidative phosphorylation capacity was analysed in tissue specimens. There was a similar maximum oxygen flux on fatty acids and tricarboxylic acid cycle derivates in chronically unloaded compared with standard heart explants. Interestingly, the respiratory control ratio, which is a surrogate marker of coupling efficiency, was significantly increased in the unloaded group compared with the standard transplant group, suggesting more efficient ATP production in these mitochondria. Analysis of myocardial mitochondrial hydrogen peroxide production between these two groups showed that reactive oxygen species production during mitochondrial respiration was decreased in tissue samples of the chronic unloaded hearts (see Figure 1 ).
In conclusion, this study found an increased mitochondrial coupling efficiency and decreased hydrogen peroxide production in chronically unloaded hearts, but no differences in maximal mitochondrial respiration when comparing those hearts haemodynamically unloaded by LVADs with hearts that were unsupported. Future research will investigate whether alterations of mitochondrial respiration occur during ventricular unloading in acute cardiogenic shock and, if so, how this may impact patient outcomes and heart recovery. Other planned studies include the impact of acute ventricular unloading on mitochondrial respiration and hydrogen peroxide production. 2 Survival at 30 days was lower in patients over 65 years old and in those who required cardiopulmonary resuscitation (CPR). Using these data, an ECMO mortality score has been developed and validated. 2 However, prolonged use of ECMO (>2 days) is associated with greatly increased mortality. 3 The use of ECMO presents a number of clinical challenges. In particular, Dr Westermann highlighted that ECMO leads to an This increased afterload is due to retrograde femoral flow in CS. This causes further ECMO-dependent increases in LV wall stress and LV pressures, conditions that are unfavourable to the patient. Therefore, there is a need to shift pressure-volume loops to the left, which can be achieved by unloading the LV. This can be achieved through transseptal methods (e.g. atrioseptostomy, TandemHeart) or the less invasive transvalvular route (e.g. Impella). Dr Westermann suggested that the use of the Impella in addition to VA-ECMO may improve outcomes in patients with CS due to LV unloading. This hypothesis was tested in a study that enrolled 157 patients with CS: 123 received VA-ECMO support and 34 had concomitant treatment with VA-ECMO and an Impella device. A propensity-matching analysis was performed in a 2:1 ratio, comparing 42 patients undergoing VA-ECMO alone (control group) with 21 patients treated with VA-ECMO and Impella. Patients in the VA-ECMO plus Impella group (termed Ecmella) had a significantly lower rate of in-hospital mortality (47 % versus 80 %; P<0.001) and a higher rate of successful bridging to either recovery or further therapy (68 % versus 28 %; P<0.001) compared with patients receiving VA-ECMO alone. 4 Similar findings have been observed in Dr Westermann's recent registry study in Hamburg (n=81). 5 There is increased haemolysis in the Ecmella group, but he indicated this did not lead to increased clinical complications. Those patients treated with ECMO/Ecmella also had significantly more rapid weaning from inotropes.
In conclusion, ECMO therapy may improve survival in CS; however, there is a lack of randomised controlled trial data. In addition, haemodynamic challenges remain with ECMO therapy in CS, including increases in afterload, LV wall stress, and pulmonary congestion. LV unloading with concomitant use of an Impella device may positively affect outcomes in patients with CS on VA-ECMO. It should be noted that data in support of 
